Back to today’s briefing

Story perspectives

SpringWorks Stays Independent; BridgeBio's Drug Thrives Amid FDA Woes

2/21/2025

35 6

Summary

Story summary

SpringWorks Therapeutics remains independent as Merck KGaA's acquisition plans falter amid canceled earnings calls. In a brighter note, BridgeBio's heart drug, Attruby, has soared with over 1,000 prescriptions. However, Eli Lilly's obesity drug raises alarms as users report alarming health risks from rapid weight loss. Meanwhile, the FDA's recent staff cuts are stalling medical device approvals, igniting frustration within the industry.

1 of 1

Story summary

SpringWorks Therapeutics remains independent as Merck KGaA's acquisition plans falter amid canceled earnings calls. In a brighter note, BridgeBio's heart drug, Attruby, has soared with over 1,000 prescriptions. However, Eli Lilly's obesity drug raises alarms as users report alarming health risks from rapid weight loss. Meanwhile, the FDA's recent staff cuts are stalling medical device approvals, igniting frustration within the industry.